Toxic Side Effects of Drugs Used to Treat Chagas’ Disease (American Trypanosomiasis)

@article{Castro2006ToxicSE,
  title={Toxic Side Effects of Drugs Used to Treat Chagas’ Disease (American Trypanosomiasis)},
  author={Jos{\'e} Alberto de Castro and Mar{\'i}a Montalto deMecca and Laura Cecilia Bartel},
  journal={Human and Experimental Toxicology},
  year={2006},
  volume={25},
  pages={471 - 479}
}
Chagas’ disease (American trypanosomiasis) is an endemic parasitic disease in some areas of Latin America. About 16-18 million persons are infected with the aetiological agent of the disease, Trypanosoma cruzi, and more than 100 million are living at risk of infection. There are different modes of infection: 1) via blood sucking vector insects infected with T. cruzi, accounting for 80-90% of transmission of the disease; 2) via blood transfusion or congenital transmission, accounting for0.5-8… 

Figures from this paper

Trypanocidal treatment of Chagas disease.
Trypanocidal treatment of Chagas disease.
Experimental and Clinical Treatment of Chagas Disease: A Review
TLDR
The literature emphasizes the urgent need for new therapies for acute and chronic CD, with the mechanism of action of the commercially available drugs, NFX and BZ, the biodistribution of the latter, and the potential for novel formulations of BZ based on nanotechnology discussed.
The urgent need to develop new drugs and tools for the treatment of Chagas disease
TLDR
The compulsory screening of T. cruzi in hemoderivatives and solid organs donated by patients from Latin America should be considered, because there are large numbers of South American immigrants who are often unaware of their infection, which has serious public health implications for the management of blood banks and healthcare provision.
American trypanosomiasis.
First century of Chagas' disease: an overview on novel approaches to nifurtimox and benzonidazole delivery systems.
  • C. Salomon
  • Medicine
    Journal of pharmaceutical sciences
  • 2012
TLDR
Different approaches carried out in the last decades for developing novel pharmaceutical formulations for the delivery of nifurtimox and benznidazole are discussed.
Efficacy and Safety of Chagas Disease Drug Therapy and Treatment Perspectives
TLDR
This chapter will address alternative therapies of comorbidities related to the progression of Chagas’ disease in patients with chronic disease, such as heart disease and dysfunction of the digestive system and novel pharmacological strategies and their related compounds will be reviewed.
[Screening for congenital infection by Trypanosoma cruzi in France].
The importance of congenital transmission of Chagas' disease increases with its emergence in communities infected with Trypanosoma cruzi, but where vector transmission has never existed or is fully
Update on oral Chagas disease outbreaks in Venezuela: epidemiological, clinical and diagnostic approaches
TLDR
As a food-borne disease, this entity requires epidemiological, clinical, diagnostic and therapeutic approaches that differ from those approaches used for traditional direct or cutaneous vector transmission.
Chagas Disease Drug Discovery
  • E. Chatelain
  • Medicine, Biology
    Journal of biomolecular screening
  • 2015
TLDR
New developments in the Chagas field, including new technologies and tools now available, will be discussed, and a redesign of the current screening strategy during the discovery process is proposed.
...
...

References

SHOWING 1-10 OF 61 REFERENCES
Chagas' Heart Disease
TLDR
The use of amiodarone, angiotensin‐converting enzyme inhibitors, and pacemaker implantation may contribute to a better survival in selected patients with cardiac involvement of chronic Chagas' disease.
Chagas' disease: lymphoma growth in rabbits treated with Benznidazole.
TLDR
Benznidazole administration caused severe cell-mediated immunosuppression in T. cruzi-infected and BCG-immunized rabbits, probably as a consequence of Chagas' heart disease and of the development of lymphomas.
Amastigotes forms of Trypanosoma cruzi detected in a renal allograft.
TLDR
It is demonstrated that T. cruzi can infect the renal parenchyma of a kidney graft recipient one month after transplantation and this mode of transmission warrants in endemic areas of Chagas' disease.
Novel antitrypanosomal agents
TLDR
This article summarises the recent progress in identifying novel lead compounds for antitrypanosomal chemotherapy and places particular emphasis on those agents showing promising, selective antitrypenosomal activity.
The impact of Chagas disease control in Latin America: a review.
TLDR
The social impact of Chagas disease control can now be readily demonstrated by the disappearance of acute cases and of new infections in younger age groups, as well as progressive reductions of mortality and morbidity rates in controlled areas.
Chagas infection transmission control: situation of transfusional transmission in Brazil and other countries of Latin America.
TLDR
The transmission of the transfusion-associated Chagas disease is an important mechanism of its dissemination in several Latin American countries, and the Southern Cone Iniciative set off by the Pan-American Health Organization, in 1991, is contributing to the implementation of blood law in each endemic country.
A critical review on Chagas disease chemotherapy.
TLDR
A historical introduction of drugs assayed against Chagas disease beginning in 1912 with the works of Mayer and Rocha Lima up to the experimental use of nitrofurazone, and a survey about new classes of synthetic and natural compounds studied after 1992/1993.
A critical review on Chagas disease chemotherapy.
TLDR
A historical introduction of drugs assayed against Chagas disease beginning in 1912 with the works of Mayer and Rocha Lima up to the experimental use of nitrofurazone, and a survey about new classes of synthetic and natural compounds studied after 1992/1993.
...
...